miconazole + L-NMMA + bradykinin

This is a **combination** of three compounds: **miconazole**, **L-NMMA** (NG-monomethyl-L-arginine), and **bradykinin). - **Miconazole** is an imidazole antifungal agent that inhibits fungal growth primarily by blocking the synthesis of ergosterol, an essential component of fungal cell membranes. It achieves this by inhibiting the enzyme CYP450 14α-lanosterol demethylase, leading to changes in cell membrane permeability and, consequently, fungal cell death[1][2][3][4]. - **L-NMMA** (NG-monomethyl-L-arginine) is a non-selective inhibitor of nitric oxide synthase (NOS), reducing the synthesis of nitric oxide, a key cellular signaling molecule. - **Bradykinin** is a peptide that acts as a potent vasodilator, increasing vascular permeability and contributing to pain and inflammatory responses; it acts on bradykinin receptors to mediate these effects. This particular combination does not appear as an approved or marketed pharmaceutical product. It likely represents an experimental or research combination and may be used in laboratory settings to probe the interactions between fungal infections, nitric oxide pathways, and vascular responses.